What each state’s law does when the FDA approves a psilocybin medicine
No psilocybin medicine is approved. When one is, it stays in federal Schedule I until the DEA issues a rule, and each state’s own law decides how it treats that one prescription drug. None of these laws changes anything for psilocybin mushrooms.
Tracker · Updated 20 Nov 2026 · Each row carries the date its statute was read
State by state, and the federal step
Eleven states have enacted a measure on what their drug schedules do once the FDA approves a psilocybin medicine. Most states also have an older, general clause that ties their schedules to a federal change, and those clauses differ in who acts, whether they must, how long they wait, and whether they reach a move to a lower schedule at all. Each row says which, in the statute’s own terms.
Each statute was read on its state’s own code or legislature host. Open a row’s “Its own words” to see the text the row rests on. A place’s name links to its register record.
Find a state All fifty and the District of Columbia, A to Z.
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
| Jurisdiction | What its law does on approval | What it waits on | Where it stands | The statute | Checked |
|---|---|---|---|---|---|
| The federal step | |||||
| Federal law | After FDA approval, the DEA must issue an interim final rule within 90 days of the later of HHS's recommendation and notice of approval. The medicine stays in Schedule I until that rule, and the approval letter decides whether approval itself waits for it. | FDA approval, then DEA rule | The sponsor says it completed its application on 9 November 2026. The FDA's 2026 approvals list, current to 19 November, names no psilocybin medicine. | 21 U.S.C. 811(j) (opens in new tab)21 U.S.C. 355(x) (opens in new tab)21 CFR 1308.11 (opens in new tab)Its own wordsHide its words21 U.S.C. 811(j)(1): 21 U.S.C. 355(x)(1): | |
| The fifty states and the District of Columbia | |||||
| Alabama | The State Board of Health must follow a federal rescheduling 30 days after the DEA's final order appears in the Federal Register, once notified, unless it objects. The text does not say if an interim final rule counts as a final order. | DEA rule, then State Board of Health | Waiting on an FDA approval. | Ala. Code 20-2-20(c) (opens in new tab)Its own wordsHide its wordsAla. Code 20-2-20(c): | |
| Alaska | The clause reaches only a substance newly added as a controlled substance under federal law. Even for that, it obliges the governor only to introduce a bill in the legislature. | DEA rule, then the legislature | Waiting on an FDA approval. | AS 11.71.120(b) (opens in new tab)Its own wordsHide its wordsAS 11.71.120(b): | |
| Arizona | Since September 2026, any FDA-approved product the DEA schedules or reschedules takes the identical schedule in Arizona's controlled substances chapter, with no Board action, and may be prescribed once outside Schedule I. Title 13 still lists psilocybin as a dangerous drug. Its section 13-3412(A)(7) exempts from section 13-3407, the dangerous-drug offense, a person lawfully holding a controlled substance that chapter authorizes. | DEA rule | SB 1188 in force since 12 September 2026. A 2025 provision for crystalline polymorph psilocybin (SB 1555) takes effect only if the federal steps come by 1 January 2031. Waiting on an FDA approval. | A.R.S. 36-2517.03 (opens in new tab)SB 1188 (2026), Laws 2026 ch. 216 (opens in new tab)A.R.S. 13-3412(A)(7) (opens in new tab)A.R.S. 36-2517.02 (opens in new tab)SB 1555 (2025), Laws 2025 ch. 231 (opens in new tab)Its own wordsHide its wordsA.R.S. 36-2517.03: A.R.S. 13-3412(A)(7): A.R.S. 36-2517.02: | |
| Arkansas | The 30-day duty reaches only a substance newly designated as controlled under federal law. A move to a lower schedule is left to the Secretary of the Department of Health, who may reschedule by rule. | DEA rule, then Secretary of Health | Waiting on an FDA approval. | Ark. Code 5-64-201(d) (opens in new tab)Read on the Board of Pharmacy's reprint; the official code host refused automated readers.Its own wordsHide its wordsArk. Code 5-64-201(d)(1): Ark. Code 5-64-201(a)(1)(A)(i): | |
| California | Once a federal rescheduling places an FDA-approved product outside Schedule I, prescribers and pharmacists acting under federal law are deemed to comply with state law. Psilocybin stays in state Schedule I, and the text leaves open whether patients are covered if only the product moves. | DEA rule | Printed as current law in the Board of Pharmacy's 2026 lawbook. Waiting on an FDA approval. | Cal. Health & Safety Code 11150.3 (opens in new tab)Cal. Health & Safety Code 11054(d) (opens in new tab)Read on the Board of Pharmacy's reprint; the official code host refused automated readers.Its own wordsHide its wordsCal. Health & Safety Code 11150.3(a): | |
| Colorado | Since August 2026, Colorado controls an FDA-approved prescription drug product as the DEA does, automatically and immediately from the DEA's effective date. Once the DEA places it outside Schedule I, it leaves Colorado's Schedule I if dispensed by a registered pharmacy or administered by a practitioner, and possessed only by an authorized person. | DEA rule | In force since August 2026 (SB 26-031) and separate from Colorado's natural medicine program. Waiting on an FDA approval. | C.R.S. 18-18-203(3), SB 26-031 (2026) (opens in new tab)HB 25-1063 (2025), C.R.S. 18-18-203(2)(c)(XXI) (opens in new tab)Its own wordsHide its wordsC.R.S. 18-18-203(3)(a): C.R.S. 18-18-203(3)(b): C.R.S. 18-18-203(3)(c): | |
| Connecticut | Federal schedules prevail automatically only where they are stricter, so a federal move to a lower schedule does not carry over if Connecticut's regulations place the drug in Schedule I. The Commissioner of Consumer Protection may change its schedule by regulation. | DEA rule, then Commissioner of Consumer Protection | Waiting on an FDA approval. | Conn. Gen. Stat. 21a-243(g) (opens in new tab)Conn. Gen. Stat. 21a-243(d) (opens in new tab)Its own wordsHide its wordsConn. Gen. Stat. 21a-243(g): Conn. Gen. Stat. 21a-243(d): | |
| Delaware | The Secretary of State may reschedule a substance only after the federal schedules change and the chapter's placement findings are made, with no time limit. Psilocybin stays in Schedule I by statute until then. | DEA rule, then Secretary of State | Waiting on an FDA approval. | 16 Del. C. 4711 (opens in new tab)Its own wordsHide its words16 Del. C. 4711: | |
| District of Columbia | The Mayor may follow a federal rescheduling, with no time limit and no automatic effect, and the text does not say whether a rule is needed to do so. Psilocybin stays in Schedule I by statute until the Mayor acts. | DEA rule, then the Mayor | Waiting on an FDA approval. | D.C. Code 48-902.01(d) (opens in new tab)Its own wordsHide its wordsD.C. Code 48-902.01(d): | |
| Florida | Florida's Attorney General may, by rule, move a substance to a less controlled schedule on finding that reduced control is in the public interest, giving great weight to federal scheduling. Short of a new statute, that rule is the only route. | DEA rule, then state Attorney General | Waiting on an FDA approval. | Fla. Stat. 893.0355(2) (opens in new tab)Its own wordsHide its wordsFla. Stat. 893.0355(2): Fla. Stat. 893.0355(3): | |
| Georgia | Once an FDA-approved crystalline polymorph psilocybin drug is DEA-scheduled and listed in 21 U.S.C. 812, it leaves Georgia's Schedule I psilocybin entry. The text names no Georgia schedule for it and does not say if a DEA rule counts as listing in 812. | DEA rule | Signed in 2026. The psilocybin section takes effect only once the drug is FDA-approved, DEA-scheduled and listed in 21 U.S.C. 812. | O.C.G.A. 16-13-22(a) (opens in new tab)HB 382 (2026), Sections 3 and 8 (opens in new tab)Read on the Board of Pharmacy's reprint; the official code host refused automated readers.Its own wordsHide its wordsHB 382 (2026), Section 3: HB 382 (2026), Section 8(b): | |
| Hawaii | Once notified, the Department of Law Enforcement must follow a federal rescheduling 30 days after the DEA's final order is published, if an interim final rule counts as one. The change is temporary and is nullified unless the next regular legislative session enacts it. | DEA rule, then Department of Law Enforcement | Waiting on an FDA approval. SB 3199, which would have covered interim final orders, died in conference in 2026. | Haw. Rev. Stat. 329-11(d) (opens in new tab)SB 3199 (2026), died in conference (opens in new tab)Its own wordsHide its wordsHaw. Rev. Stat. 329-11(d): Haw. Rev. Stat. 329-11(d): | |
| Idaho | The board must follow a federal rescheduling within 30 days of the DEA's final order being published, by temporary rule or a proposed statutory amendment, unless it objects. The text does not say if an interim final rule counts as a final order. | DEA rule, then the board | Waiting on an FDA approval. | Idaho Code 37-2702(d) (opens in new tab)Its own wordsHide its wordsIdaho Code 37-2702(d): | |
| Illinois | A federal rescheduling is deemed to apply 30 days after the DEA's final order is published, even without Department action, unless the Department or an adversely affected party objects, which brings a public hearing within 45 days and a decision within 14 days of it. The text does not say if an interim final rule counts as a final order. | DEA rule | The day-30 rule has been in force since 7 August 2026 (P.A. 104-0819). Waiting on an FDA approval. | 720 ILCS 570/201(d) (opens in new tab)P.A. 104-0819 (2026) (opens in new tab)Its own wordsHide its words720 ILCS 570/201(d): | |
| Indiana | A federal move to a less restrictive schedule follows automatically, with no state act. If the board objects within 30 days of the federal change, the move is held until the end of the next complete session of the General Assembly. | DEA rule | Waiting on an FDA approval. | Ind. Code 35-48-2-1(e) (opens in new tab)Its own wordsHide its wordsInd. Code 35-48-2-1(e): Ind. Code 35-48-2-1(e): | |
| Iowa | The 30-day duty covers only a new substance designated under federal law. A move to a lower schedule goes to the General Assembly as the board's recommendation, so the schedule changes only by statute. | DEA rule, then the legislature | Waiting. HF 383, which would have moved the approved drug out of Schedule I, passed both chambers and was vetoed on 11 June 2025. | Iowa Code 124.201(4) (opens in new tab)HF 383 (2025), vetoed (opens in new tab)Its own wordsHide its wordsIowa Code 124.201(4): | |
| Kansas | Kansas has no clause that follows a federal change. The Board of Pharmacy only reports proposed reschedulings to the legislature each year, so psilocybin stays in Schedule I until the legislature amends the act. | DEA rule, then the legislature | Waiting. HB 2218, which would have listed the approved product in Schedule IV, was stricken from the House calendar on 19 February 2026. | K.S.A. 65-4102(b) (opens in new tab)HB 2218 (2026), stricken from calendar (opens in new tab)Its own wordsHide its wordsK.S.A. 65-4102(b): | |
| Kentucky | A federal rescheduling follows automatically, with no waiting period: the drug is controlled in Kentucky in the same numerical schedule as the federal one. The Cabinet for Health and Family Services may instead regulate it into a more restrictive schedule. | DEA rule | Waiting on an FDA approval. | KRS 218A.020(3) (opens in new tab)902 KAR 55:015 (opens in new tab)Its own wordsHide its wordsKRS 218A.020(3)(a): 902 KAR 55:015, Section 4(1): | |
| Louisiana | The health secretary may, in an adjudication, transfer a substance to match its DEA schedule, with no time limit, and a transfer leaves the statute's penalties unchanged. Whether the approved product counts instead as an addition, which the secretary must make, the text leaves open. | DEA rule, then health secretary | Waiting on an FDA approval. | La. R.S. 40:962(D) (opens in new tab)Its own wordsHide its wordsLa. R.S. 40:962(D): La. R.S. 40:962(G): | |
| Maine | Maine's drug schedules are set by statute for defining crimes, and none follows federal scheduling. Psilocybin stays in Schedule X, and the text does not say whether an approved prescription product containing it stays there or falls to Schedule Z. | DEA rule, then the legislature | Waiting on an FDA approval. | 17-A M.R.S. 1102 (opens in new tab)Its own wordsHide its words17-A M.R.S. 1102: 17-A M.R.S. 1102(4)(A): | |
| Maryland | Maryland's Schedules II to V take in whatever the federal government designates in them, unless the Department objects, so a federal placement of the approved medicine follows automatically. The text does not say which schedule governs while psilocybin itself stays federally in Schedule I. | DEA rule | Waiting on an FDA approval. | Md. Code, Crim. Law 5-202(f) (opens in new tab)Md. Code, Crim. Law 5-405(a) (opens in new tab)Its own wordsHide its wordsMd. Code, Crim. Law 5-405(a): Md. Code, Crim. Law 5-202(f): | |
| Massachusetts | The commissioner must act within 30 days only for a substance not yet scheduled or moved to a stricter schedule, and may move one to a lower schedule. Section 2(a) also has the state's schedules incorporate the federal schedules and any amendment of them. The text does not reconcile the two, or say whether the approved product counts as not yet scheduled. | DEA rule, then the commissioner | Waiting on an FDA approval. | Mass. Gen. Laws c. 94C, s. 2(a1/2) (opens in new tab)Mass. Gen. Laws c. 94C, s. 2(a) (opens in new tab)Its own wordsHide its wordsMass. Gen. Laws c. 94C, s. 2(a1/2): Mass. Gen. Laws c. 94C, s. 2(a1/2): Mass. Gen. Laws c. 94C, s. 2(a): | |
| Michigan | Once the Board of Pharmacy is notified, the approved medicine must be scheduled in Michigan as it is federally, unless the board meets within 60 days of notice to decide whether to follow. The text sets no deadline for the scheduling itself. | DEA rule, then Board of Pharmacy | Waiting on an FDA approval. | MCL 333.7204 (opens in new tab)Its own wordsHide its wordsMCL 333.7204: | |
| Minnesota | The Board of Pharmacy may follow a federal rescheduling by an order that expires within 12 months and cannot be renewed. The text does not say how the change becomes permanent, since the board may not otherwise reschedule a Schedule I drug. | DEA rule, then Board of Pharmacy | Waiting on an FDA approval. | Minn. Stat. 152.02, subd. 12(a) (opens in new tab)Its own wordsHide its wordsMinn. Stat. 152.02, subd. 12(a): Minn. Stat. 152.02, subd. 8: | |
| Mississippi | Once the DEA schedules an FDA-approved crystalline polymorph psilocybin composition, it is automatically placed on the matching state schedule, with that schedule's penalties. This lasts only until a statute amends the schedule or the next regular legislative session ends, whichever comes first. | DEA rule | In force since 1 July 2026 and waiting. Once triggered, it holds only until the schedules are amended or the next regular session ends. | Miss. Code 41-29-111(1)(d) (opens in new tab)SB 2056 (2026), Section 1 (opens in new tab)Read in the enacted bill; the code host refused automated readers.Its own wordsHide its wordsSB 2056 (2026), Section 1: SB 2056 (2026), Section 1: | |
| Missouri | Once notified, the Department of Health and Senior Services must follow a federal rescheduling and submit emergency rules within 30 days of the DEA's final order, unless it objects. The text does not say if an interim final rule counts as a final order. | DEA rule, then Department of Health and Senior Services | Waiting on an FDA approval. | Mo. Rev. Stat. 195.015.4 (opens in new tab)Its own wordsHide its wordsMo. Rev. Stat. 195.015.4: | |
| Montana | Once notified, the Board of Pharmacy must follow a federal rescheduling 30 days after the DEA's final order is published, unless it objects. The text does not say if an interim final rule counts as a final order. | DEA rule, then Board of Pharmacy | Waiting on an FDA approval. | Mont. Code Ann. 50-32-203 (opens in new tab)Its own wordsHide its wordsMont. Code Ann. 50-32-203: | |
| Nebraska | The statute already takes an FDA-approved pharmaceutical composition of crystalline polymorph psilocybin out of Schedule I and lists it in Schedule IV, on FDA approval alone. Federal Schedule I still applies until the DEA's rule, and a different DEA schedule would need another statute. | DEA rule | Enacted by LB 72, approved 25 February 2025, and in the current code. Waiting on an FDA approval. | Neb. Rev. Stat. 28-405 (opens in new tab)LB 72 (2025) (opens in new tab)Its own wordsHide its wordsNeb. Rev. Stat. 28-405, Schedule I(c)(12): Neb. Rev. Stat. 28-405, Schedule IV(g): | |
| Nevada | Not read yet. The state’s official code host would not serve it to us, so this row waits for a reading by hand. | Not read yet | Not read yet. | NRS 453.146 (opens in new tab) | Not read yet |
| New Hampshire | Once notified, the health and human services commissioner must follow a federal rescheduling 30 days after the DEA's final order is published, unless the commissioner objects. The text does not say if an interim final rule counts as a final order. | DEA rule, then health and human services commissioner | Waiting on an FDA approval. | RSA 318-B:1-a, V (opens in new tab)Its own wordsHide its wordsRSA 318-B:1-a, V: | |
| New Jersey | Not read yet. The state’s official code host would not serve it to us, so this row waits for a reading by hand. | Not read yet | Not read yet. | N.J.S.A. 24:21-3 (opens in new tab) | Not read yet |
| New Mexico | The Board of Pharmacy may, by regulation after a hearing, control a substance designated under federal law, with no time limit. The clause names designation only, and FDA-approved psilocybin products are exempt from the state's Medical Psilocybin Act. | DEA rule, then Board of Pharmacy | Waiting on an FDA approval. | NMSA 1978, 30-31-3(C) (opens in new tab)NMSA 1978, 26-2D-4 (opens in new tab)Its own wordsHide its wordsNMSA 1978, 30-31-3(C): NMSA 1978, 26-2D-4: | |
| New York | If the DEA moves the approved product out of Schedule I, the health commissioner must reclassify it by regulation or emergency regulation, into the federal schedule or a less restrictive one, or exempt it. The text sets no deadline. | DEA rule, then health commissioner | Waiting on an FDA approval. | N.Y. Pub. Health Law 3307(5) (opens in new tab)Read in the enacted bill; the code host refused automated readers.Its own wordsHide its wordsS8618 (2022), the Legislature's summary: | |
| North Carolina | Not read yet. The state’s official code host would not serve it to us, so this row waits for a reading by hand. | Not read yet | Not read yet. | N.C. Gen. Stat. 90-88 (opens in new tab) | Not read yet |
| North Dakota | The statute already lists COMP360, or its FDA-approved trade name, in state Schedule IV, but federal Schedule I applies until the DEA's rule. If the DEA chooses another schedule, the general clause directs the Board of Pharmacy to follow it after 30 days. | DEA rule | In force since 26 March 2025. Waiting on an FDA approval. | N.D.C.C. 19-03.1-02(4) (opens in new tab)N.D.C.C. 19-03.1-11(7) (opens in new tab)SB 2064 (2025) (opens in new tab)Its own wordsHide its wordsN.D.C.C. 19-03.1-11(7): N.D.C.C. 19-03.1-02(4): | |
| Ohio | Not read yet. The state’s official code host would not serve it to us, so this row waits for a reading by hand. | Not read yet | Not read yet. | R.C. 3719.43 (opens in new tab) | Not read yet |
| Oklahoma | Under a general rule for FDA-approved prescription drugs, the approved medicine leaves Schedule I and follows federal law once the DEA issues a notice, final rule or interim final rule rescheduling it, unless and until the Board of Pharmacy acts. | DEA rule | Waiting on an FDA approval. | 63 O.S. 2-204(H) (opens in new tab)63 O.S. 2-201 (opens in new tab)Its own wordsHide its words63 O.S. 2-204(H): | |
| Oregon | Oregon's schedules follow the federal ones through Board of Pharmacy rules that cite dated federal texts. On the rules' words, a DEA placement after those dates enters the state list only when the board amends them, which it may do with no deadline. | DEA rule, then Board of Pharmacy | Waiting on an FDA approval. | ORS 475.005(6)(a), 475.035(2) (opens in new tab)OAR 855-080-0020 (opens in new tab)Its own wordsHide its wordsOAR 855-080-0020: OAR 855-080-0021(1): | |
| Pennsylvania | The Secretary of Health may reschedule a substance to match federal law on finding that public health and safety will not be harmed, and a move to a lower schedule may take effect when published in the Pennsylvania Bulletin. | DEA rule, then Secretary of Health | Waiting on an FDA approval. | 35 P.S. 780-103(c)(1) (opens in new tab)Its own wordsHide its words35 P.S. 780-103(c)(1): | |
| Rhode Island | Rhode Island's list of controlled substances is the current Title 21 of the federal regulations, which the director of health must reference, so a DEA placement changes it with no waiting period unless the director objects. | DEA rule | Waiting on an FDA approval. | R.I. Gen. Laws 21-28-2.01(a)(1), (c) (opens in new tab)Its own wordsHide its wordsR.I. Gen. Laws 21-28-2.01(a)(1), (c): R.I. Gen. Laws 21-28-2.01(c): | |
| South Carolina | The Director of the Department of Public Health must mirror a federal rescheduling within 30 days after the DEA's final order is published, if an interim final rule counts as one. The change has the force of law unless the General Assembly overturns it. | DEA rule, then Department of Public Health | Waiting on an FDA approval. | S.C. Code 44-53-160(C) (opens in new tab)Its own wordsHide its wordsS.C. Code 44-53-160(C): S.C. Code 44-53-160(C): | |
| South Dakota | The statute already takes an FDA-approved crystalline polymorph psilocybin drug product out of Schedule I and lists it in Schedule IV, on FDA approval alone. Federal Schedule I still applies until the DEA's rule, and only the legislature can follow a different federal schedule. | DEA rule | In force since 1 July 2026, the default date for an act that names none. Waiting on an FDA approval. | SDCL 34-20B-27 (opens in new tab)SDCL 34-20B-25(65) (opens in new tab)HB 1099 (2026) (opens in new tab)Its own wordsHide its wordsSDCL 34-20B-14(18): SDCL 34-20B-25(65): | |
| Tennessee | Not read yet. The state’s official code host would not serve it to us, so this row waits for a reading by hand. | Not read yet | Not read yet. | Tenn. Code Ann. 39-17-403(d)(1) (opens in new tab) | Not read yet |
| Texas | The state health commissioner must reschedule the approved medicine after a 30-day period that starts the day after the DEA's final order is published, unless the commissioner objects. Psilocybin also stays listed by statute in Penalty Group 2, a list outside this clause. | DEA rule, then health commissioner | Waiting on an FDA approval. | Tex. Health & Safety Code 481.034(g) (opens in new tab)Tex. Health & Safety Code 481.103 (opens in new tab)Its own wordsHide its wordsTex. Health & Safety Code 481.034(g): Tex. Health & Safety Code 481.103(a)(1): | |
| Utah | A federal rescheduling follows automatically: once the federal government places an FDA-approved composition of a Schedule I substance in a schedule other than Schedule I, Utah deems it scheduled in that same schedule, with no state act and no waiting period. | DEA rule | In force since 6 May 2026. Waiting on an FDA approval. | Utah Code 58-37-108(3) (opens in new tab)S.B. 83 (2026) (opens in new tab)Its own wordsHide its wordsUtah Code 58-37-108(3)(b): Utah Code 58-37-108(3)(a): | |
| Vermont | Vermont keeps no drug schedules, so it has nothing to reschedule. Psilocybin is a hallucinogenic drug by statute, and section 4214(a) lets a licensed physician prescribe, administer and dispense regulated drugs, a class that includes hallucinogenic drugs. The text does not say how federal scheduling bears on that. | DEA rule | Waiting on an FDA approval. | 18 V.S.A. 4201(10) (opens in new tab)18 V.S.A. 4214(a) (opens in new tab)Its own wordsHide its words18 V.S.A. 4201(10): 18 V.S.A. 4201(29): 18 V.S.A. 4214(a): | |
| Virginia | If the FDA approves a psilocybin formulation for a health care professional to give in a health care setting, the Board of Pharmacy must reschedule it at its next quarterly meeting after 30 days from the DEA's final or interim final order or rule. | DEA rule, then Board of Pharmacy | Enacted in 2026 as chapters 305 and 306. Waiting on an FDA approval. | Va. Code 54.1-3443(E) (opens in new tab)2026 Va. Acts ch. 305 (opens in new tab)2026 Va. Acts ch. 306 (opens in new tab)Its own wordsHide its words2026 Va. Acts ch. 305: Va. Code 54.1-3443(E): | |
| Washington | The Pharmacy Quality Assurance Commission must follow a federal rescheduling 30 days after the DEA's final order is published, unless it or any interested party objects. The text does not say if an interim final rule counts as a final order. | DEA rule, then Pharmacy Quality Assurance Commission | Waiting on an FDA approval. | RCW 69.50.201(d) (opens in new tab)Its own wordsHide its wordsRCW 69.50.201(d): | |
| West Virginia | Once the FDA approves and the DEA reschedules a drug containing an organic psilocybin substance or crystalline polymorph psilocybin, it becomes lawful to prescribe, distribute and market it, and the Schedule I psilocybin entry excepts it. The text does not say which state schedule then applies. | DEA rule | In force since 12 June 2026. Waiting on an FDA approval. | W. Va. Code 60A-2-201(d) (opens in new tab)W. Va. Code 60A-2-201(g) (opens in new tab)SB 906 (2026) (opens in new tab)Its own wordsHide its wordsW. Va. Code 60A-2-201(g): W. Va. Code 60A-2-201(d): W. Va. Code 60A-2-204(d): | |
| Wisconsin | Once notified, the Controlled Substances Board must follow a federal rescheduling by affirmative action 30 days after the DEA's final order is published, unless it or an interested party objects. The text does not say if an interim final rule counts as a final order. | DEA rule, then Controlled Substances Board | Waiting on an FDA approval. | Wis. Stat. 961.11(4) (opens in new tab)Its own wordsHide its wordsWis. Stat. 961.11(4): | |
| Wyoming | The attorney general, as commissioner, must control the approved medicine as federal law does, by emergency rule, within 30 days of notice and no later than 30 days after the change first appears in the Federal Register, unless the commissioner objects. | DEA rule, then attorney general | Waiting on an FDA approval. | Wyo. Stat. 35-7-1011(d) (opens in new tab)Its own wordsHide its wordsWyo. Stat. 35-7-1011(d): | |
Changes to this page
Named the 2026 act behind Illinois’s day-30 rule, P.A. 104-0819, in force since 7 August, and the hearing clock an objection starts. Arizona’s row now gives the date its 2026 law took effect, 12 September, and the Title 13 section that keeps a lawful holder outside the dangerous-drug offense.
Corrected five rows. Arizona and Colorado passed laws in 2026, SB 1188 and SB 26-031, under which an FDA-approved drug the DEA reschedules takes the federal schedule with no further state act; our first reading missed both. Vermont’s row now cites section 4214(a), which lets a physician prescribe regulated drugs, and no longer lists its legislature as a step. The Massachusetts row adds section 2(a), and the West Virginia row says its Schedule I psilocybin entry excepts the approved drug.
First version. Every state’s scheduling law read on its own host, the federal step read at govinfo and eCFR, and the fourteen psilocybin measures read again.
Get an email when this table changes
One email when the FDA acts on a psilocybin medicine and one when the DEA’s rule is published, each saying which rows of this table changed. The same list gets our monthly roundup.
We never send spam or share your address, and you can unsubscribe at any time, as the privacy statement explains.